A report of drug reactions with HER2-Positive BC from the Italian pharmacovigilance database, showed serious AEs reports of anti-HER2 therapy mainly involved the following: thrombocytopenia, diarrhea, asthenia, cardiac failure, vomiting, hypersensitivity, ejection fraction decreased and stomatitis [20]. Here, ERBB2 is linked to Thrombocytopenia.